MedDataX Logo

Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)

NCT ID: NCT03399578

Last Updated: 2021-10-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

29 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-14

Study Completion Date

2021-09-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a clinical trial in which healthy volunteers will be administered an experimental MERS vaccine. The vaccine ChAdOx1 MERS will be administered alone both as a single administration and with a homologous prime-booster.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All vaccinations will be administered intramuscularly. In Groups 1-3, each volunteer will receive one vaccination in total. In Groups 4 and 5, each volunteer will receive two vaccinations in total.

There are five different vaccine schedules:

Group 1 (n=6) will receive 5 x 10\^9 vp ChAdOx1 MERS .

Group 2 (n=9) will receive 2.5 x 10\^10 vp ChAdOx1 MERS.

Group 3 (n=9) will receive 5 x 10\^10 vp ChAdOx1 MERS.

Group 4 (n=6-12) will receive 2.5 x 10\^10 vp ChAdOx1 MERS at week 0 followed by a boost of 2.5 x 10\^10 vp ChAdOx1 MERS at week 26.

Group 5 (n=6-12) will receive 2.5 x 10\^10 vp ChAdOx1 MERS at week 0 followed by a boost of 2.5 x 10\^10 vp ChAdOx1 MERS at week 4.

The study will assess the safety of the vaccines, and the immune responses to the vaccinations. Immune responses are measured by tests on blood samples.

Healthy adult volunteers will be recruited in Oxford, England.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

MERS (Middle East Respiratory Syndrome)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Group 1 volunteers (n= 6) will be administered ChAdOx1 MERS, 5 x 10\^9 vp through intramuscular route.

Group Type EXPERIMENTAL

ChAdOx1 MERS

Intervention Type BIOLOGICAL

The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.

Group 2

Group 2 volunteers (n= 9) will be administered ChAdOx1 MERS, 2.5 x 10\^10 vp through intramuscular route.

Group Type EXPERIMENTAL

ChAdOx1 MERS

Intervention Type BIOLOGICAL

The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.

Group 3

Group 3 volunteers (n= 9) will be administered ChAdOx1 MERS, 5 x 10\^10 vp through intramuscular route.

Group Type EXPERIMENTAL

ChAdOx1 MERS

Intervention Type BIOLOGICAL

The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.

Group 4

Group 4 volunteers (n=6-12) will be administered ChAdOx1 MERS, 2.5 x 10\^10 vp at week 0, followed by ChAdOx1 MERS, 2.5 x 10\^10 vp at week 26. Both administrations will be given through intramuscular route.

Group Type EXPERIMENTAL

ChAdOx1 MERS

Intervention Type BIOLOGICAL

The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.

Group 5

Group 5 volunteers (n=6-12) will be administered ChAdOx1 MERS, 2.5 x 10\^10 vp at week 0, followed by ChAdOx1 MERS, 2.5 x 10\^10 vp at week 4. Both administrations will be given through intramuscular route.

Group Type EXPERIMENTAL

ChAdOx1 MERS

Intervention Type BIOLOGICAL

The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ChAdOx1 MERS

The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

The volunteer must satisfy all the following criteria to be eligible for the study:

1. Healthy adults aged 18 to 50 years
2. Able and willing (in the Investigator's opinion) to comply with all study requirements
3. Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner or access this medical history electronically.
4. For females only, willingness to practice continuous effective contraception during the study and a negative pregnancy test on the day(s) of screening and vaccination
5. Agreement to refrain from blood donation during the course of the study
6. Provide written informed consent

Exclusion Criteria

The volunteer may not enter the study if any of the following apply:

1. Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period
2. Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccine).
3. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
4. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)
5. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
6. Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.
7. Any history of anaphylaxis in relation to vaccination
8. Pregnancy, lactation or willingness/intention to become pregnant during the study
9. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
10. History of serious psychiatric condition likely to affect participation in the study
11. Bleeding disorder (eg. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture
12. Any other serious chronic illness requiring hospital specialist supervision
13. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week
14. Suspected or known injecting drug abuse in the 5 years preceding enrolment
15. Seropositive for hepatitis B surface antigen (HBsAg)
16. Seropositive for hepatitis C virus (antibodies to HCV)
17. Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis
18. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
19. Inability of the study team to contact the volunteer's GP to confirm medical history and safety to participate
20. Prior exposure to MERS-CoV (serology will be requested at the discretion of the investigator)
21. History of allergic reaction to Aminoglycoside antibiotics
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Oxford

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Adrian V Hill, DPhil FRCP

Role: PRINCIPAL_INVESTIGATOR

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital

Oxford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Folegatti PM, Bittaye M, Flaxman A, Lopez FR, Bellamy D, Kupke A, Mair C, Makinson R, Sheridan J, Rohde C, Halwe S, Jeong Y, Park YS, Kim JO, Song M, Boyd A, Tran N, Silman D, Poulton I, Datoo M, Marshall J, Themistocleous Y, Lawrie A, Roberts R, Berrie E, Becker S, Lambe T, Hill A, Ewer K, Gilbert S. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 2020 Jul;20(7):816-826. doi: 10.1016/S1473-3099(20)30160-2. Epub 2020 Apr 21.

Reference Type DERIVED
PMID: 32325038 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MERS001

Identifier Type: -

Identifier Source: org_study_id